Benign prostatic hyperplasia.

selective antagonist of post-synaptic alpha-1 adrenoreceptors

Bioavailability: 32%
Protein binding: 97%
Metabolism: Extensive via CYP3A4, glucuronidation, and alcohol and aldehyde dehydrogenase pathways
Excretion: Feces (55%); urine (34%)
Elimination half-life: 5 - 21 hr

Concurrent use with strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, ritonavir); severe renal impairment (Clcr <30 mL/minute); severe hepatic impairment (Child-Pugh class C)

B. however silodosin is not approved for use in women.

Silodosin is not intended for use in women.

Retrograde ejaculation (28%), Dizziness (3%), Orthostatic hypotension (3%), headache (2%), nasopharyngitis (2.4%), Nasal congestion (2.1%)

8 mg once daily with a meal

CrCl >50 mL/minute: No dosage adjustment necessary.
CrCl 30-50 mL/minute: 4 mg once daily.
CrCl <30 mL/minute: Use is contraindicated.

Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C): Use is contraindicated (has not been studied).